N-[4-(3-bromo-phenyl)-1H-imidazol-2-yl]-acetamide | 842155-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[4-(3-bromo-phenyl)-1H-imidazol-2-yl]-acetamide
• 英文别名: N-[5-(3-bromophenyl)-1H-imidazol-2-yl]acetamide
• CAS: 842155-14-0
• 化学式: C₁₁H₁₀BrN₃O
• 分子量: 280.124
• InChiKey: ADBKJRHTEGGNGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[4-(3-bromo-phenyl)-1H-imidazol-2-yl]-acetamide 在 盐酸 、 甲醇 、 水 作用下， 反应 4.0h， 以86%的产率得到4-(3-bromophenyl)-1H-imidazol-2-ylamine hydrochloric acid salt
  参考文献：
  名称：

  WO2006/76702

  摘要：

  公开号：
• 作为产物：
  描述：

  N-乙酰基胍 、 2,3-二溴苯乙酮 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 0.05h， 以40%的产率得到N-[4-(3-bromo-phenyl)-1H-imidazol-2-yl]-acetamide
  参考文献：
  名称：

  [EN] 5-HT2B RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DU RECEPTEUR 5-HT2B

  摘要：

  化合物的分子式：（I）、（II）、（IIIa）、（IIIb）、（IVa）和（IVb）：或其药用可接受的盐，用作药物，特别用于治疗通过拮抗5-HT2B受体缓解的病症。

  公开号：

  WO2005012263A1

文献信息

• [EN] 5-HT2B RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR 5-HT2B
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005012263A1

  公开（公告）日：2005-02-10

  Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.

  化合物的分子式：（I）、（II）、（IIIa）、（IIIb）、（IVa）和（IVb）：或其药用可接受的盐，用作药物，特别用于治疗通过拮抗5-HT2B受体缓解的病症。
• 5-Ht2b Receptor Antagonists
  申请人：Borman Richard Anthony

  公开号：US20090018150A1

  公开（公告）日：2009-01-15

  Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT 2B receptor.

  化合物的分子式为：(I)，(II)，(IIIa)，(IIIb)，(IVa)和(IVb)；或其药学上可接受的盐，用于制作药品，特别是用于治疗通过5-HT2B受体拮抗缓解的疾病。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Dhar Murali T.G.

  公开号：US20070179189A1

  公开（公告）日：2007-08-02

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C 2-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, R a , R b , R c and R d are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型的非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用处，包括肥胖症、糖尿病、炎症和免疫性疾病，并具有以下结构的式子(I)或(II)：包括其立体异构体、互变异构体、前药或药物可接受的盐，其中Q选择自N、O和S；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含该化合物的药物组合物和治疗肥胖、糖尿病和炎症或免疫相关疾病的方法。
• MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Dhar T.G. Murali

  公开号：US20100113532A1

  公开（公告）日：2010-05-06

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C 2-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, R a , R b , R c and R d are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非甾体化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中有用，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构为公式（I）或（II）：包括其立体异构体、互变异构体、前药或其药学上可接受的盐，其中Q从N、O和S中选择；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含该化合物的制药组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US07642273B2

  公开（公告）日：2010-01-05

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型的非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖症、糖尿病、炎症和免疫性疾病，其结构式为(I)或(II)：包括其立体异构体、互变异构体、前药或其药学上可接受的盐，其中Q选自N、O和S；Y为芳基或杂环芳基；Z为H、C2-6烷基、环烷基、杂环烷基、芳基、杂环芳基、卤素或烷氧基；A、B、R、Ra、Rb、Rc和Rd在此定义。还提供了包含该化合物的药物组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。